Intention-to-treat analysis keeps all trial data, showing true drug effects, even with dropouts. It contrasts with per-protocol analysis, where dropout data is excluded, possibly skewing results.
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback